Catalio Capital Management, LP: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1958125) · Explore on the interactive board
Catalio Capital Management, LP disclosed 39 US equity positions worth $532.1m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is AVALYN PHARMACEUTICALS INC at 10.4% of the reported book, followed by JNJ, GILD. The top ten holdings are 56.7% of the book, and the portfolio behaves like about 22 equal-weight positions. Versus the prior filing it opened 11 new positions, added to 15, reduced 8 and exited 13. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Catalio Capital Management, LP own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 11 new, 15 added, 8 reduced, 13 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | AVALYN PHARMACEUTICALS INC | 10.4% | $55.2m | 1,675,830 | – | new | |
| 2 | JNJ JOHNSON & JOHNSON | Healthcare | 6.6% | $35.3m | 138,946 | – | new |
| 3 | GILD GILEAD SCIENCES INC | Healthcare | 6.4% | $34.0m | 269,309 | 64% | added |
| 4 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 6.4% | $33.9m | 455,041 | 5% | added |
| 5 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 5.0% | $26.6m | 1,215,698 | 16% | added |
| 6 | DFTX DEFINIUM THERAPEUTICS INC | Healthcare | 5.0% | $26.5m | 562,672 | -46% | reduced |
| 7 | BMY BRISTOL-MYERS SQUIBB CO | Healthcare | 4.5% | $23.8m | 412,961 | -2% | reduced |
| 8 | PARABILIS MEDICINES INC | 4.2% | $22.6m | 824,043 | – | new | |
| 9 | NTRA NATERA INC | Healthcare | 4.2% | $22.3m | 82,181 | 16% | added |
| 10 | INCY INCYTE CORP | Healthcare | 4.1% | $21.7m | 191,627 | 5% | added |
| 11 | SEPN SEPTERNA INC | Healthcare | 3.4% | $18.0m | 536,152 | 82% | added |
| 12 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 3.3% | $17.5m | 648,722 | 48% | added |
| 13 | HTFL HEARTFLOW INC | Healthcare | 3.2% | $17.1m | 583,055 | 44% | added |
| 14 | CRVS CORVUS PHARMACEUTICALS INC | Healthcare | 3.0% | $16.1m | 1,080,888 | 21% | added |
| 15 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 2.8% | $14.8m | 276,550 | 8% | added |
| 16 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 2.5% | $13.1m | 106,799 | – | new |
| 17 | IRON DISC MEDICINE INC | Healthcare | 2.2% | $11.7m | 159,384 | 30% | added |
| 18 | EW EDWARDS LIFESCIENCES CORP | Healthcare | 2.1% | $11.3m | 124,778 | -14% | reduced |
| 19 | AXSM AXSOME THERAPEUTICS INC. | Healthcare | 2.0% | $10.6m | 43,182 | – | new |
| 20 | RARE ULTRAGENYX PHARMACEUTICAL IN | Healthcare | 2.0% | $10.6m | 316,252 | -63% | reduced |
| 21 | KAILERA THERAPEUTICS INC | 1.9% | $10.3m | 468,750 | – | new | |
| 22 | KPTI KARYOPHARM THERAPEUTICS INC | 1.7% | $9.2m | 940,855 | 5% | added | |
| 23 | ODYSSEY THERAPEUTICS INC | 1.6% | $8.6m | 457,839 | – | new | |
| 24 | ASND ASCENDIS PHARMA A/S | Healthcare | 1.6% | $8.5m | 31,759 | – | new |
| 25 | KARD KARDIGAN INC | 1.4% | $7.5m | 312,500 | – | new | |
| 26 | ELDN ELEDON PHARMACEUTICALS INC | 1.3% | $6.7m | 1,695,071 | 3% | added | |
| 27 | FDMT 4D MOLECULAR THERAPEUTICS IN | Healthcare | 1.2% | $6.3m | 471,254 | – | new |
| 28 | MANE VERADERMICS INC | Healthcare | 1.1% | $5.6m | 45,856 | -74% | reduced |
| 29 | DYN DYNE THERAPEUTICS INC | Healthcare | 1.0% | $5.4m | 244,929 | -13% | reduced |
| 30 | GUTS FRACTYL HEALTH INC | 0.9% | $4.9m | 6,168,749 | 12% | added | |
| 31 | IMCR IMMUNOCORE HLDGS PLC | Healthcare | 0.9% | $4.7m | 148,045 | 76% | added |
| 32 | DNTH DIANTHUS THERAPEUTICS INC | Healthcare | 0.6% | $3.2m | 32,941 | -94% | reduced |
| 33 | BBOT BRIDGEBIO ONCOLOGY THERAPEUT | 0.5% | $2.4m | 318,407 | – | new | |
| 34 | TARA PROTARA THERAPEUTICS INC | 0.4% | $2.0m | 520,148 | -10% | reduced | |
| 35 | HYPR HYPERFINE INC | 0.3% | $1.8m | 1,320,041 | 0% | held | |
| 36 | ATAI ATAIBECKLEY INC | 0.2% | $1.0m | 196,858 | 0% | held | |
| 37 | MGX METAGENOMI THERAPEUTICS INC | 0.1% | $629.5k | 528,993 | 0% | held | |
| 38 | OM OUTSET MED INC | 0.1% | $511.0k | 118,279 | 0% | held | |
| 39 | FTH FAETH THERAPEUTICS INC | 0.1% | $367.9k | 14,718 | 0% | held |
What did Catalio Capital Management, LP sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| ASND ASCENDIS PHARMA A/S | 20.2% | $29.5m |
| 430 TERNS PHARMACEUTICALS INC | 14.7% | $21.6m |
| SLNOEUR SOLENO THERAPEUTICS INC | 13.2% | $19.3m |
| BSX BOSTON SCIENTIFIC CORP | 12.8% | $18.8m |
| CYTK CYTOKINETICS INC | 9.7% | $14.2m |
| ADPT ADAPTIVE BIOTECHNOLOGIES COR | 6.8% | $10.0m |
| 4XC1 KALVISTA PHARMACEUTICALS INC | 5.9% | $8.6m |
| UNIQURE NV | 5.5% | $8.0m |
| ABVX ABIVAX SA | 3.6% | $5.3m |
| SUPN SUPERNUS PHARMACEUTICALS | 2.2% | $3.2m |
| PHAT PHATHOM PHARMACEUTICALS INC | 1.9% | $2.8m |
| NEWAMSTERDAM PHARMA COMPANY | 1.8% | $2.7m |
| TYRA TYRA BIOSCIENCES INC | 1.8% | $2.6m |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 74.9% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Catalio Capital Management, LP's portfolio?
Across every quarter Catalio Capital Management, LP has filed, its median largest position is 10.1% of the book and its median top-ten weight is 55.6%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 12.0 completed holding spells, the median lasted 1.0 quarters; 39.0 positions are still open and their final length is unknown.